

Factors Influencing Concordance Between Clinical and Ultrasound Findings in Rheumatoid Arthritis

MARION Le BOEDEC, SANDRINE JOUSSE-JOULIN, JEAN-FRANÇOIS FERLET, THIERRY MARHADOUR, GÉRARD CHALES, LAURENT GRANGE, CÉCILE HACQUARD-BOUDER, DAMIEN LOEUILLE, JÉRÉMIE SELLAM, JEAN-DAVID ALBERT, JACQUES BENTIN, ISABELLE CHARY-VALCKENAERE, MARIA-ANTONIETTA D'AGOSTINO, FABIEN ETCHEPARE, PHILIPPE GAUDIN, CHRISTOPHE HUDRY, MAXIME DOUGADOS, and ALAIN SARAUX

ABSTRACT. Objective. Clinical joint examination (CJE) is less time-consuming than ultrasound (US) in rheumatoid arthritis (RA). Low concordance between CJE and US would indicate that the 2 tests provide different types of information. Knowledge of factors associated with CJE/US concordance would help to select patients and joints for US. Our objective was to identify factors associated with CJE/US concordance.

Methods. Seventy-six patients with RA requiring tumor necrosis factor- α (TNF- α) antagonist therapy were included in a prospective, multicenter cohort. In each patient, 38 joints were evaluated. Synovitis was scored using CJE, B-mode US (B-US), and power Doppler US (PDUS). Joints whose kappa coefficient (κ) for agreement CJE/US was < 0.1 were considered discordant. Multivariate analysis was performed to identify factors independently associated with CJE/US concordance, defined as factors yielding $p < 0.05$ and $OR > 2$.

Results. Concordance between TNF- α antagonist therapy varied across joints for CJE/US ($\kappa = -0.08$ to 0.51) and B-US/PDUS ($\kappa = 0.30$ to 0.67). CJE/US concordance was low at the metatarsophalangeal joints and shoulders ($\kappa < 0.1$). Before TNF- α antagonist therapy, a low 28-joint Disease Activity Score (DAS28) was associated with good CJE/B-US concordance, and no factors were associated with CJE/PDUS concordance. After TNF- α antagonist therapy, only the joint site was associated with CJE/B-US concordance; joint site and short disease duration were associated with CJE/PDUS concordance.

Conclusion. Concordance between CJE and US is poor overall. US adds information to CJE, most notably at the metatarsophalangeal joints and shoulders. Usefulness is decreased for B-US when DAS28 is low and for PDUS when disease duration is short. (J Rheumatol First Release Jan 15 2013; doi:10.3899/jrheum.120843)

Key Indexing Terms:

ULTRASONOGRAPHY

SYNOVITIS

RHEUMATOID ARTHRITIS

From Rheumatology, Centre Hospitalier Universitaire (CHU) Brest, Brest; Statistics, RCTS, Lyon; Rheumatology, CHU, Rennes; Rheumatology, CHU, Grenoble; Rheumatology, APHP, Paris Boulogne; Rheumatology, CHU, Nancy; Rheumatology, CHU, Paris Saint Antoine; Rheumatology, CHU, Paris Boulogne; Rheumatology, CHU, Pitié, Paris; Rheumatology, APHP, Cochin, Paris, France; and Rheumatology, CHU, Brugmann, Belgium.

Supported by an unrestricted grant from Abbott France.

M. Le Boedec, MD; S. Jousse-Joulin, MD, Rheumatology, CHU Brest; J-F. Ferlet, PhD, Statistics, RCTS; T. Marhadour, MD, Rheumatology, CHU Brest; G. Chales, MD, Rheumatology, CHU, Rennes; L. Grange, MD, Rheumatology, CHU, Grenoble; C. Hacquard-Bouder, MD, Rheumatology, APHP, Paris Boulogne; D. Loeuille, MD, PhD, Rheumatology, CHU, Nancy; J. Sellam, MD, PhD, Rheumatology, CHU, Paris Saint Antoine; J-D. Albert, MD, Rheumatology, CHU, Rennes; J. Bentin, MD, Rheumatology, CHU, Brugmann; I. Chary-Valckenaere, MD, PhD, Rheumatology, CHU, Nancy; M-A. d'Agostino, MD, PhD, Rheumatology, CHU, Paris Boulogne; F. Etchepare, MD, Rheumatology, CHU, Pitié, Paris; P. Gaudin, MD, PhD, Rheumatology, CHU, Grenoble; C. Hudry, MD; M. Dougados, MD, Rheumatology, APHP, Cochin, Paris; A. Saraux, MD, PhD, Rheumatology, CHU Brest.

Dr. M. Le Boedec and Dr. S. Jousse-Joulin contributed equally to this report.

Address correspondence to Prof. A. Saraux, Rheumatology Unit, la Cavale Blanche Hospital, Brest Teaching Hospital, BP 814, F 29609 Brest-Cedex, France. E-mail: Alain.Saraux@univ-brest.fr

Accepted for publication November 27, 2012.

Rheumatoid arthritis (RA) is a systemic inflammatory disease that results in cartilage and bone destruction. The number of joints with synovitis by clinical joint examination (CJE) is a relevant measure of disease activity. However, CJE may fail to detect all joints with synovitis^{1,2}. Patients in clinical remission may have subclinical synovitis associated with a risk of structural disease progression^{3,4,5}.

Numerous studies have proven that ultrasonography (US) using both B-mode and power-Doppler (PD) mode is more sensitive than CJE for detecting synovitis and that PD ultrasonography (PDUS) provides information on the degree of inflammation^{6,7,8,9,10,11,12}. In a previous study, findings by B-mode US (B-US), PDUS, and CJE independently predicted radiographic progression¹³. Recently, Dougados, *et al* confirmed the validity of clinical and/or sonographic synovitis for predicting 2-year structural deterioration in RA¹⁴. Further, synovial hypervascularization regresses under combined biologic and disease-modifying antirheumatic drug (DMARD) therapy, suggesting that US may assist in evaluating the response to treatment over time^{15,16,17,18,19,20}.

The use of US has been criticized because the results are heavily operator-dependent. However, the OMERACT group (Outcome Measures in Rheumatoid Arthritis Clinical Trials) developed definitions of US abnormalities in various joints, with the goal of improving the reliability and other metrological properties of joint US^{21,22,23}. The main problem now is that concordance between CJE and US may vary across joints. Such variability may explain why studies of US findings in a limited number of joints showed good agreement with CJE^{24,25,26}.

CJE is less time-consuming than US. The time needed for US can be decreased by limiting the evaluation to joints where discordances with CJE findings are most likely to occur. Therefore, it would help to identify factors that influence CJE/US concordance at specific joints in the individual patient.

The objectives of our study were to evaluate concordance between CJE and US (B-US, PDUS, and both modes in combination) for detecting synovitis in patients with active RA before and after tumor necrosis factor- α (TNF- α) antagonist therapy and to identify factors associated with good concordance.

MATERIALS AND METHODS

We conducted a prospective, multicenter, 4-month study of patients with RA referred to the study centers by their rheumatologists for TNF- α antagonist therapy. The study was approved by the appropriate ethics committees. All patients gave their written informed consent.

Patients. Patients older than age 18 years who met 1987 American College of Rheumatology (ACR) criteria for RA²⁷ were eligible if they were referred to the study centers for TNF- α antagonist therapy in 2007 or 2008. A swollen joint count of 6 or more as assessed by CJE was required. Patients were evaluated at baseline and after 4 months of TNF- α antagonist therapy. For all patients, 2 investigators worked in pairs (clinical investigator and US investigator) during the 4-month study.

Clinical joint evaluation. In each of the 9 study centers, a single investigator (research nurse or rheumatologist) with experience in clinical metrology in RA, blinded to the US data, was in charge of monitoring the patients. Demographics were collected at baseline including sex, age, disease duration, history of surgery related to RA, and previous RA treatments. In each patient, the investigator determined the counts on 66 joints according to ACR recommendations. At each joint, synovitis was scored semiquantitatively (0, definitely no synovitis; 1, doubtful; 2, moderate; 3, obvious and important; clinical synovitis defined by score of at least 2 joints) and a binary score (presence of synovitis, yes/no), but the binary score was used only for the present study.

The following data were collected at the baseline and Month 4 visits: tender joint count (on 68 joints), patient's global assessment using a 0–100 visual analog scale (VAS), functional impairment using the Health Assessment Questionnaire-Disability Index (HAQ-DI), and physician's global assessment of disease activity using a 0–100 VAS.

The US evaluation. The US evaluation was performed on 38 joints, including the 28 joints of the DAS28 [shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees] and the metatarsophalangeal (MTP) joints. US was performed in a dimly lit room. In each of the 9 study centers, a single experienced sonographer (radiologist in 1 center or rheumatologist in others) who was blinded to the CJE data performed all the US evaluations for the study. Their intraobserver and interobserver reproducibility were fair to good (0.37 to 0.75).

Multiplanar greyscale (B-mode) and PD images were obtained using commercial real-time scanners (Esaote Technos MPX, Toshiba Aplio, Esaote MyLab, Philips HD11, or BK Mini Focus) and multifrequency linear transducers (7–12 MHz). US scanning techniques, greyscale (B-mode) and PD machine settings, and definitions of abnormalities were standardized before the study during a 1.5-day meeting of all 9 study sonographers^{28,29}. PD measurements were adjusted to the lowest permissible pulse repetition frequency (PRF) to maximize sensitivity, which led to PRF values as low as 750 Hz. Low-wall filters were used. Color gain was set just below the level at which color noise appeared in the underlying bone. Synovitis was defined according to OMERACT definitions as a grade of at least 1 for B-mode (hypoechoic thickening of the synovial membrane that was nondisplaceable and poorly compressible) and PD mode independently^{21,22}. B-mode and PD mode measure different aspects of inflammation that can be combined to define synovitis, but we considered each of them separately for statistical analysis. Both B-US and PDUS were recorded for each joint. On B-US images, synovitis was scored using a 0 to 3 scale with these subjective definitions for each grade: 0, no synovial thickening; 1, mild synovial thickening; 2, moderate synovial thickening; and 3, marked synovial thickening. For PDUS images, a 0 to 3 scale was also used, with these definitions: 0, no signal and no intraarticular flow; 1, mild, signal from 1–2 vessels (including 1 confluent vessel) for small joints and 2–3 vessels (including 2 confluent vessels) for large joints; 2, moderate vessel confluence (> grade 1) occupying < 50% of the normal synovial surface area; and 3, marked vessel confluence occupying > 50% of the normal synovial surface area.

Statistics. Concordance between synovitis by CJE and synovitis (grade 1 or higher) by B-US, PDUS, or B-US + PDUS at baseline was assessed by computing the kappa coefficient (κ) for each of the 38 joints. Concordance between B-US and PDUS for the presence of grade 1 synovitis was also assessed by computing κ . Joints with κ values < 0.1 were considered discordant and removed from the assessment of factors associated with CJE/US concordance. For the remaining joints, univariate logistic regression was used to look for an effect on CJE/US concordance of age, sex, body mass index (BMI, kg/m²), disease duration, history of RA-related surgery, HAQ score, DAS28, erythrocyte sedimentation rate (ESR), physician's and patient's global assessments, and rheumatoid factor (RF). Factors yielding p values < 0.05 by univariate analysis were entered into a multivariate logistic regression model. Factors that yielded p values < 0.05 in the multivariate model and that had OR > 2 were classified as significantly affecting CJE/US concordance.

RESULTS

Patients. During the study period, 76 patients met our study selection criteria and were included. After the baseline CJE and US evaluation, 66 patients returned for the second visit at Month 4.

Of the 76 patients, 64 were female (84%); mean age was 55 ± 13 years and mean disease duration 10 ± 9 years. Only 16 patients (21.05%) had a disease duration < 2 years. Tests for RF were positive in 59 patients (78%). A history of RA-related surgery was noted in 21 patients (27.5%). All patients received at least 1 DMARD. The mean number of previous DMARD was 3 ± 2 . Of the 76 patients, 52 were naive to TNF- α antagonist therapy, 15 were taking TNF- α antagonist therapy with unsatisfactory results, and 8 had taken TNF- α antagonist therapy in the past; information on prior TNF- α antagonist therapy was missing for 1 patient.

At baseline, mean DAS28 ESR was 5.12 ± 1.31 (5.22 ± 1.23 in the group with disease duration < 2 yrs and $5.19 \pm$

1.34 in the group with disease duration > 2 yrs), mean C-reactive protein (CRP) was 18 ± 19 mg/l, and mean HAQ score was 1.41 ± 0.68 . At Month 4, 66 patients returned for the second visit; mean DAS28 ESR was 3.47 ± 1.37 , mean CRP was 8 ± 13 mg/l, and mean HAQ score was 1.0 ± 0.7 . There was not any difference of characteristics for the distinct disease duration subgroups at baseline.

Concordance between the CJE and US. For CJE versus B-US of all joints, concordance was 63.2% at baseline before TNF- α antagonist therapy and 69.5% after 4 months of TNF- α antagonist therapy. Corresponding values for CJE versus PDUS were 75.2% and 84.0%.

CJE versus US concordance rates at baseline (Table 1) varied across joints ($\kappa = -0.08$ to 0.51). Concordance was

lowest at the MTP joints ($\kappa = -0.08$ to 0.28) and shoulders ($\kappa = -0.08$ to 0.05), which were excluded from the evaluation of factors associated with concordance.

At all joints, fewer cases of synovitis were detected by PDUS than by B-US, indicating a greater sensitivity of B-US. Results of the analysis using B-US or PDUS findings were similar to those of the analysis using only B-US findings. Consequently, we assessed concordance of CJE with B-US and with PDUS but not with both B-US and PDUS or with either B-US or PDUS.

Concordance between B-US and PDUS. At baseline, concordance between B-mode and PD findings was fair to moderate and varied across joints (Table 2). Thus, κ ranged from 0.3 for the first MTP joint to 0.67 for the fourth PIP

Table 1. Concordance (κ) at baseline between synovitis by clinical joint examination (CJE) and a synovitis grade of 1 or more by B-mode ultrasonography (B-US) or power Doppler ultrasonography (PDUS).

Clinical Synovitis Joint Site		Sonographic Synovitis								
		B-US+			PDUS+			B-US+ or PDUS+		
		Yes	No	κ (95% CI)	Yes	No	κ (95% CI)	Yes	No	κ (95% CI)
Shoulder	Yes	4	4	0.05 (−0.06; 0.15)	0	8	−0.08 (−0.12; −0.04)	4	4	0.04 (−0.06; 0.14)
	No	47	97		19	125		50	94	
Elbow	Yes	15	9	0.25 (0.10; 0.41)	10	14	0.27 (0.08; 0.46)	15	9	0.24 (0.09; 0.40)
	No	34	94		17	111		35	93	
Wrist	Yes	74	12	0.16 (0.02; 0.30)	62	24	0.29 (0.14; 0.45)	75	11	0.18 (0.04; 0.32)
	No	46	19		28	37		46	19	
MCP1	Yes	56	16	0.36 (0.22; 0.51)	40	33	0.42 (0.29; 0.56)	56	16	0.36 (0.22; 0.51)
	No	32	46		10	68		32	46	
MCP2	Yes	67	11	0.34 (0.20; 0.48)	52	26	0.49 (0.35; 0.62)	67	11	0.34 (0.20; 0.48)
	No	38	35		13	60		38	35	
MCP3	Yes	50	20	0.41 (0.26; 0.55)	38	32	0.44 (0.31; 0.58)	51	19	0.42 (0.28; 0.56)
	No	25	57		9	73		25	57	
MCP4	Yes	18	14	0.23 (0.07; 0.39)	13	19	0.32 (0.14; 0.50)	18	14	0.23 (0.07; 0.39)
	No	34	86		13	107		34	86	
MCP5	Yes	34	11	0.39 (0.25; 0.53)	21	24	0.40 (0.23; 0.56)	34	11	0.39 (0.25; 0.53)
	No	33	73		11	95		33	73	
PIP1	Yes	31	15	0.32 (0.17; 0.47)	15	30	0.33 (0.17; 0.49)	31	15	0.32 (0.17; 0.47)
	No	34	72		6	100		34	72	
PIP2	Yes	38	18	0.40 (0.25; 0.54)	21	35	0.31 (0.16; 0.46)	38	18	0.38 (0.24; 0.53)
	No	26	70		9	87		27	69	
PIP3	Yes	49	21	0.51 (0.37; 0.64)	28	42	0.35 (0.22; 0.48)	49	21	0.51 (0.37; 0.64)
	No	16	66		5	77		16	66	
PIP4	Yes	22	19	0.37 (0.20; 0.53)	17	24	0.40 (0.24; 0.57)	22	19	0.37 (0.20; 0.53)
	No	19	92		7	104		19	92	
PIP5	Yes	14	18	0.18 (0.01; 0.35)	7	25	0.16 (−0.01; 0.34)	14	18	0.18 (0.01; 0.35)
	No	28	92		10	110		28	92	
Knee	Yes	25	15	0.22 (0.07; 0.37)	10	30	0.20 (0.03; 0.37)	25	15	0.22 (0.07; 0.37)
	No	39	69		9	99		39	69	
MTP1	Yes	5	7	−0.05 (−0.13; 0.03)	1	11	−0.08 (−0.18; 0.03)	5	7	−0.05 (−0.13; 0.03)
	No	83	53		29	107		83	53	
MTP2	Yes	12	4	0.03 (−0.04; 0.10)	11	5	0.28 (0.12; 0.45)	12	4	0.03 (−0.04; 0.10)
	No	88	47		29	106		88	47	
MTP3	Yes	13	7	0.03 (−0.07; 0.12)	10	10	0.23 (0.06; 0.41)	77	54	0.03 (−0.07; 0.12)
	No	77	54		25	106		13	7	
MTP4	Yes	8	7	0.02 (−0.08; 0.12)	4	11	0.10 (−0.08; 0.29)	8	7	0.02 (−0.08; 0.12)
	No	65	71		19	117		65	71	
MTP5	Yes	9	7	0.06 (−0.05; 0.17)	5	11	0.05 (−0.10; 0.21)	9	7	0.06 (−0.05; 0.17)
	No	57	79		31	105		57	79	

MCP: metacarpophalangeal joint; PIP: proximal interphalangeal joint; MTP: metatarsophalangeal joint.

Table 2. Concordance (κ) at baseline between a synovitis grade of 1 or more by B-mode ultrasonography (B-US) versus power Doppler ultrasonography (PDUS).

Joint Site	B-US Grade ≥ 1	PDUS Grade ≥ 1		κ (95% CI)
		Yes	No	
Shoulder	Yes	16	35	0.34 (0.19; 0.48)
	No	3	98	
Elbow	Yes	26	23	0.59 (0.45; 0.73)
	No	1	102	
Wrist	Yes	89	31	0.52 (0.39; 0.65)
	No	1	30	
MCP1	Yes	50	39	0.51 (0.40; 0.63)
	No	—	62	
MCP2	Yes	65	40	0.50 (0.39; 0.62)
	No	—	47	
MCP3	Yes	46	29	0.60 (0.49; 0.72)
	No	1	76	
MCP4	Yes	26	26	0.57 (0.43; 0.70)
	No	—	100	
MCP5	Yes	32	35	0.50 (0.38; 0.63)
	No	—	84	
PIP1	Yes	21	43	0.36 (0.24; 0.48)
	No	—	87	
PIP2	Yes	29	35	0.48 (0.35; 0.61)
	No	1	87	
PIP3	Yes	33	32	0.54 (0.42; 0.67)
	No	—	87	
PIP4	Yes	24	17	0.67 (0.54; 0.81)
	No	—	111	
PIP5	Yes	17	25	0.50 (0.34; 0.65)
	No	—	110	
Knee	Yes	19	47	0.31 (0.19; 0.43)
	No	—	85	
MTP1	Yes	30	58	0.30 (0.20; 0.40)
	No	—	60	
MTP2	Yes	40	60	0.31 (0.21; 0.41)
	No	—	51	
MTP3	Yes	35	55	0.34 (0.24; 0.44)
	No	—	61	
MTP4	Yes	23	50	0.32 (0.21; 0.44)
	No	—	78	
MTP5	Yes	36	30	0.58 (0.45; 0.70)
	No	—	86	

MCP: metacarpophalangeal joint; PIP: proximal interphalangeal joint; MTP: metatarsophalangeal joint.

joint. In each joint, PDUS was positive only when B-US also showed synovitis.

Factors associated with concordance between the CJE and US. By multivariate analysis, factors associated with good concordance ($p < 0.05$) at baseline were as follows: for CJE versus B-US, DAS28 and RF; and for CJE versus PDUS, RA duration, DAS28, age, and sex (Table 3). After 4 months of TNF- α antagonist therapy, the following differences were noted: for CJE vs B-US the significant factors were joint site, sex, BMI, RA duration, HAQ score, and DAS28; and for CJE/PDUS they were joint site, BMI, RA duration, HAQ score, DAS28, and RF.

The OR values for each factor at baseline versus the reference value (Table 4) showed that factors associated with good CJE/B-US concordance were low DAS28 and positive RF. However, the OR was > 2 only for low DAS28 (compared with DAS28 > 5.1 , which had the lowest concordance). Factors associated with good CJE/PDUS concordance were age > 50 years, being female, and DAS28 indicating moderate disease activity, whereas semi-recent RA (2–5 years) was associated with a low concordance. However, none of these factors was associated with an OR > 2 .

After 4 months of TNF- α antagonist therapy (Table 5), factors associated with good CJE/B-US concordance were joint site, being male, low BMI, disease duration < 5 years, HAQ score indicating moderate disability, and low DAS28. However, OR > 2 were found only for joint site (elbow, MCP 4 and 5, PIP 2, 3, 4, and knee). Factors associated with good CJE/PDUS concordance were joint site, low BMI, recent disease progression, HAQ score indicating moderate disability, low DAS28, and positive RF; OR > 2 occurred for joint site (elbow, MCP 4 and 5, PIP 1, 2, 3, 4, and 5, and knee; compared with wrist, which had the lowest concordance) and short disease duration (compared with > 10 yrs disease duration).

Table 6 summarizes the main data. CJE/US concordance was poor for the MTP joints and shoulders and for the wrists after 4 months of TNF- α antagonist therapy. At baseline, only low DAS28 was associated with good CJE/B-US agreement, and no factors were associated with CJE/PDUS concordance. After 4 months of TNF- α antagonist therapy, only joint site was associated with CJE/B-US concordance; and joint site and short disease duration were associated with good CJE/PDUS concordance.

DISCUSSION

Although US may be considered a gold standard for synovitis detection, many studies have demonstrated the usefulness of CJE in defining RA activity and in predicting RA outcome, whereas data remain scarce for US. Our goal was to select the joints with the more important US/CJE concordance or discordance. In this study, concordance between CJE and US was poor overall. Similarly, previous studies^{7,29,30,31,32,33,34,35,36,37,38,39} reported only modest correlations between CJE and US findings in patients with RA.

Our study suggests that shoulder and MTP joints are clearly discordant using CJE and US evaluation and that among the other joints, some patients' characteristics and some joint sites are associated with a good concordance. However, factors associated with good concordance are not similar before and after TNF- α antagonist therapy.

At baseline, i.e., at a time of high disease activity (defined by the clinician on the basis of elevated DAS28, elevated corticosteroid dosage, or rapid radiological progression), only low DAS28 (≤ 3.2) affected CJE/US

Table 3. Factors associated with concordance (multivariate analysis) between clinical joint examination (CJE) and ultrasonography in B-mode (B-US) or power Doppler mode (PDUS) at baseline and after 4 months of TNF- α antagonist therapy. The data are p values.

	Baseline		Month 4	
	CJE vs B-US	CJE vs PDUS	CJE vs B-US	CJE vs PDUS
Joint	0.202	0.063	< 0.0001	< 0.0001
Age	0.358	0.031	0.457	0.435
Sex	0.109	0.019	0.019	0.607
BMI	0.327	0.988	0.025	0.030
RA duration	0.054	< 0.0001	0.005	0.004
Surgery	0.212	0.403	0.134	0.185
HAQ	0.180	0.571	0.023	0.003
DAS28 ESR	< 0.0001	0.007	0.002	0.042
RF	0.048	0.188	0.409	0.031

TNF: tumor necrosis factor; BMI: body mass index; RA: rheumatoid arthritis; HAQ: Health Assessment Questionnaire score; DAS28: Disease Activity Score on 28 joints, computed using the erythrocyte sedimentation rate; RF: positive test for rheumatoid factor.

Table 4. Factors associated with baseline concordance between synovitis by clinical joint examination (CJE) and by B-mode ultrasonography (B-US) or power Doppler (PDUS). The data are OR (95% CI).

CJE vs B-US		CJE vs B-US ≥ 1		
Factor	Value (n)	Concordance Rate (%)	OR (95% CI)	p vs Reference Value
DAS28 ESR	≤ 3.2 (208)	80.3	2.26 (1.46; 3.49)	< 0.001
	3.2–5.1 (624)	72.0	1.61 (1.22; 2.12)	< 0.001
	> 5.1 (985; reference)	65.3	—	—
RF	Positive (1536)	71.4	1.31 (1.00; 1.71)	0.048
	Negative or unknown (441; reference)	62.4	—	—
CJE vs PDUS		CJE vs PDUS ≥ 1		
Age, yrs	< 40 (208)	77.4	0.71 (0.44; 1.14)	0.157
	40–50 (416)	71.4	0.66 (0.47; 0.93)	0.019
	50–60 (674)	74.9	1.06 (0.77; 1.44)	0.736
	> 60 (669; reference)	74.6	—	—
Sex	Male (309; reference)	67.3	—	—
	Female (1658)	75.6	1.52 (1.07; 2.15)	0.019
Disease duration, yrs	< 2 (414)	77.8	1.33 (0.93; 1.90)	0.124
	2–5 (337)	60.5	0.58 (0.42; 0.80)	< 0.001
	5–10 (361)	80.6	1.41 (0.97; 2.05)	0.068
	> 10 (855; reference)	75.4	—	—
DAS28 ESR	≤ 3.2 (208)	79.8	1.35 (0.88; 2.09)	0.174
	3.2–5.1 (624)	77.4	1.57 (1.17; 2.10)	0.002
	> 5.1 (985; reference)	70.7	—	—

DAS28 ESR: Disease Activity Score on 28 joints computed using the erythrocyte sedimentation rate; RF: rheumatoid factor.

concordance. After 4 months of TNF- α antagonist therapy, joint site (for both B-US and PDUS) and disease duration (for PDUS only) were associated with CJE/US concordance. Concordance at M4 was highest for MCP 4 and 5, the PIP joints, the elbows, and the knees; and lowest for the MTP joints and shoulders. Luukkainen, *et al* also reported poor correlations between CJE and US at the MTP joints ($\kappa = 0.165$)³² and shoulders³³. Concerning the relatively good concordance in the elbow, studies reported similar results using a posterior view, and that may be explained by the superficial position of the joint in its posterior part³⁴.

CJE/US concordance was not significantly affected by sex, BMI, HAQ score, or RF positivity. Short disease duration was associated with better CJE/PDUS concordance. Acute synovitis is probably easier to detect clinically in the early stages of RA than in longstanding disease, when joint damage and periarticular fibrosis without active inflammation may be mistaken for acute synovitis.

B-US and PDUS are known to provide different types of information on the same joints in patients with RA, and the US definition of synovitis includes findings from both modes^{21,22}. B-US is important to detect the main abnormal-

Table 5. Factors associated with concordance after 4 months of TNF- α antagonist therapy between synovitis by clinical joint examination (CJE) and by B-mode ultrasonography (B-US) or power Doppler (PDUS). Data are OR (95% CI).

CJE vs B-US		CJE vs B-US ≥ 1		
Factor	Value (n)	Concordance Rate (%)	OR (95% CI)	p Value vs Reference
Joint	Elbow (131)	77.9	3.01 (1.72; 5.27)	< 0.001
	Wrist (129; reference)	53.5		
	MCP1 (131)	61.1	1.31 (0.78; 2.20)	0.302
	MCP2 (131)	62.6	1.41 (0.84; 2.37)	0.196
	MCP3 (131)	64.9	1.57 (0.93; 2.65)	0.091
	MCP4 (131)	78.6	3.16 (1.80; 5.54)	< 0.0001
	MCP5 (131)	72.5	2.41 (1.40; 4.15)	0.002
	PIP1 (131)	64.9	1.57 (0.93; 2.65)	0.091
	PIP2 (131)	83.2	4.57 (2.51; 8.34)	< 0.0001
	PIP3 (131)	78.6	3.16 (1.80; 5.54)	< 0.0001
	PIP4 (131)	85.5	5.17 (2.79; 9.58)	< 0.0001
	PIP5 (130)	81.5	3.86 (2.16; 6.92)	< 0.0001
	Knee (132)	77.3	3.48 (1.97; 6.17)	< 0.0001
	Sex			
	Male (312; reference)	68.9	—	—
BMI, kg/m ²	Female (1389)	74.0	0.66 (0.47; 0.93)	0.019
	< 18.5 (52)	72.1	1.50 (0.67; 3.37)	0.325
	18.5–25 (819)	78.8	1.50 (1.04; 2.16)	0.030
	25–30 (494)	75.5	0.98 (0.67; 1.43)	0.906
Disease duration, yrs	≥ 30 (310; reference)	68.8	—	—
	< 2 (362)	68.4	1.50 (0.67; 3.37)	0.325
	2–5 (338)	78.8	1.50 (1.04; 2.16)	0.030
	5–10 (337)	75.5	0.98 (0.67; 1.43)	0.906
HAQ	> 10 (664; reference)	68.8		
	0–1 (855)	68.4	0.90 (0.56; 1.46)	0.676
	1–2 (690)	73.7	1.41 (0.89; 2.21)	0.140
DAS28 ESR	2–3 (156; reference)	73.3		
	≤ 3.2 (766)	62.2	1.88 (0.98; 3.60)	0.058
	3.2–5.1 (754)	78.5	1.06 (0.59; 1.91)	0.840
CJE vs PDUS	> 5.1 (156; reference)	67.9		
	Factor			
	Value (n)			
	Concordance Rate (%)			
	OR (95% CI)			
	p value vs Reference			
	Joint			
	Elbow (131)	81.7	2.05 (1.11; 3.75)	0.021
	Wrist (129; reference)	67.4	—	—
	MCP1 (131)	78.6	1.66 (0.92; 2.99)	0.091
	MCP2 (131)	71.0	1.11 (0.63; 1.94)	0.722
	MCP3 (131)	70.2	1.06 (0.61; 1.86)	0.832
	MCP4 (131)	87.0	3.16 (1.64; 6.11)	< 0.001
	MCP5 (131)	82.4	2.29 (1.23; 4.25)	0.009
	PIP1 (131)	85.5	2.95 (1.54; 5.64)	0.001
	PIP2 (131)	90.1	4.78 (2.31; 9.87)	< 0.0001
	PIP3 (131)	84.0	2.43 (1.30; 4.54)	0.005
	PIP4 (131)	87.0	3.16 (1.64; 6.11)	< 0.001
	PIP5 (131)	84.0	2.43 (1.30; 4.54)	0.005
	Knee (132)	84.1	2.43 (1.30; 4.54)	0.005
BMI, kg/m ²	< 18.5 (52)	86.5	1.43 (0.55; 3.69)	0.458
	18.5–25 (820)	83.8	1.49 (0.96; 2.31)	0.077
	25–30 (494)	76.1	0.87 (0.57; 1.35)	0.547
	≥ 30 (310; reference)	79.7	—	—
Disease duration, yrs	< 2 (362)	84.3	2.09 (1.31; 3.32)	0.002
	2–5 (338)	76.6	0.96 (0.63; 1.46)	0.859
	5–10 (338)	84.6	1.36 (0.85; 2.18)	0.199
	> 10 (664; reference)	79.7		
HAQ	0–1 (856)	82.5	1.03 (0.60; 1.75)	0.927
	1–2 (690)	82.5	1.86 (1.13; 3.07)	0.014
	2–3 (156; reference)	66.7		
DAS28 ESR	≤ 3.2 (766)	86.0	1.93 (0.95; 3.90)	0.069
	3.2–5.1 (754)	79.4	1.22 (0.65; 2.29)	0.534
	> 5.1 (156; reference)	62.2		
RF	Positive (1262)	82.5	1.45 (1.04; 2.04)	0.031
	Negative or unknown (440; reference)	76.8		

MCP: metacarpophalangeal joint; PIP: proximal interphalangeal joint; MTP: metatarsophalangeal joint; BMI: body mass index; HAQ: Health Assessment Questionnaire score; DAS28 ESR: Disease Activity Score on 28 joints, computed using the erythrocyte sedimentation rate; RF: positive test for rheumatoid factor.

Table 6. Factors associated with concordance at baseline and after 4 months of tumor necrosis factor antagonist therapy (M4). Poor concordance was defined as $\kappa < 0.1$ or $p < 0.05$ and $OR < 0.5$. Good concordance was defined as $p < 0.05$ and $OR > 2$.

	Good Concordance		Poor Concordance	
	B-US	PDUS	B-US	PDUS
Baseline	DAS28 ESR ≤ 3.2		Joint site: Shoulder, MTP	Joint site: Shoulder, MTP
M4	Joint site: Elbow MCP 4, 5 PIP 2, 3, 4, 5 Knee	Joint site: Elbow MCP 4, 5 PIP1, 2, 3, 4, 5 Knee Disease duration < 2 yrs	Joint site: Shoulder MTP Wrist	Joint site: Shoulder MTP Wrist

B-US: B-mode ultrasonography; PDUS: power Doppler ultrasonography; DAS28 ESR: Disease Activity Score on 28 joints computed using the erythrocyte sedimentation rate; MCP: metacarpophalangeal joint; PIP: proximal interphalangeal joint; MTP: metatarsophalangeal joint.

lities produced by synovitis and to determine whether the definition of synovitis is met. Jousse-Joulin, *et al*²⁸ showed that US can perform better or worse than CJE depending on the cutoff used to define synovitis. B-US was more sensitive than CJE with a cutoff of 1, but not with a cutoff of 2 or higher. The number of joints with synovitis by PDUS was consistently lower than by CJE, regardless of the cutoff used.

OMERACT recommendations define synovitis as a B-US or PDUS grade > 1. In our study, all joints with PDUS grades > 1 also had B-US grades > 1. This finding seems to support the use of B-US without PDUS in patients with RA. However, in longstanding RA, synovitis by B-US without a positive PDUS signal is taken to indicate remission, whereas synovitis by B-US with a PDUS signal is classified as acute synovitis. In the study by Jousse-Joulin, *et al*²⁸, a positive PDUS signal showing subclinical synovitis was more common in younger patients with recent-onset RA, whereas synovitis by B-US was more common in older patients with longstanding RA. Thus, both B-US and PDUS are useful for evaluating RA synovitis, although PDUS more specifically detects active inflammation^{3,4,5}.

A major strength of our study is that CJE and US were performed by different physicians, who were blinded to the results of the other investigations. In addition, all physicians were experienced in the investigation they performed, and all sonographers attended a 1.5-day training session on criteria for synovitis outcome measures^{28,29}. The main weakness of our study is that the data were collected by many different physicians and on different machines with different PD settings and performances (sensitivity), but it is the best way to evaluate agreement between the sonographers and clinicians. Previous studies have documented interobserver variability in CJE and US findings^{2,12}.

There is no consensus about the number and location of the joints that are most relevant for monitoring patients with RA. In several studies, monitoring a limited number of joints was reliable^{25,26} and in others the treatment response evaluation was unaffected by the number of joints included in the US scores³⁵. A study of several US scoring systems

for RA synovitis established that US was at least as relevant as CJE³⁶. In our study, as in others^{32,33}, concordance between CJE and US was low at the MTP joints and shoulders. In future studies, MTP joints and shoulders should be evaluated routinely by US, even in the absence of clinical abnormalities. In patients with RA considered in remission, US often showed persistent active inflammation, which predominated at the second and third MCP joints and correlated with the DAS28³⁷. Ankles were not included because our goal was to evaluate CJE/US concordance on the joints used for the DAS evaluation. It could be interesting to evaluate all joints in future studies.

An unexpected finding was that some clinical synovitis found by clinical investigators was not confirmed in sonography (less often in shoulders and MTP joints). This may be due to lack of experience or because of tenosynovitis, which has not been evaluated by US because it was not in the definition of US synovitis. In a knee evaluation, US was found to be more sensitive than CJE in the detection of suprapatellar bursitis, knee effusion, and Baker's cyst⁷.

The US definition of synovitis, the mode used, and joints assessed have changed over time³⁸. The optimal number and location of joints to be assessed in patients with RA needs to be determined. The development of a global score at the patient level would be helpful. The OMERACT group is developing the Global OMERACT Synovitis Score as a tool for obtaining additional information about CJE in a way that is consistent with the constraints of everyday practice.

Achieving clinical remission is now a realistic objective in patients with RA. However, patients in clinical remission may have persistent synovitis as seen by US and magnetic resonance imaging (MRI) and may therefore be at risk for further structural damage. Thus, patient followup should probably rely not only on physical evaluations, laboratory tests, and radiographs, but also on US evaluations³⁷. US and MRI have been found to be more sensitive and more specific than CJE and radiographs for assessing synovial inflammation and structural damage^{39,40}. Consequently, they are of interest for monitoring patients with RA in remission. In a comparison of US and MRI that used

OMERACT definitions to evaluate remission, the baseline B-US synovitis count predicted relapse and the baseline PDUS synovitis count predicted erosions^{41,42}.

Our study of 76 patients with active RA documented discordances between CJE and US (B-US and/or PDUS) in their detection of synovitis of grade 1 or higher. B-US was more sensitive than PDUS for detecting synovitis. Many factors were associated with CJE/US concordance, both before and after TNF- α antagonist therapy. These factors differed between B-US and PDUS. It is difficult to select patients or joint sites justifying CJE or US evaluation, except for MTP joints, shoulders, and wrists, which had the lowest CJE/US concordance. The performance of a combination of CJE (for MCP, PIP, elbow, and knee) and B-mode US (for MTP joints, shoulders, and wrists) in predicting RA outcomes by comparison with the swollen joint count used in the DAS28 should be further evaluated. It would be interesting in clinical practice and clinical trials to have a global scoring system before initiating or stopping treatment. For further study, the best way could be to compare 3 groups in predicting outcomes: 1 with CJE only, 1 with US evaluation only, and 1 with a combination of CJE (used for the joints with good concordance) and US (used for the joints with lower concordance).

ACKNOWLEDGMENT

We thank the investigators who recruited and/or monitored patients: Pierre Bourgeois, Maxime Breban, Françoise Carbonnelle, Tiffen Couchouron, Pascal Guggenbuhl, Rachida Inaoui, Catherine Le Boulout, Xavier Mariette, Jean-Marcel Meadeb, Anne Miquel and Valerie Devauchelle-Pensec.

REFERENCES

1. Wakefield RJ, Green MJ, Marzo-Ortega H, Conaghan PG, Gibbon WW, McGonagle D, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. *Ann Rheum Dis* 2004;63:382-5.
2. Salaffi F, Filippucci E, Carotti M, Naredo E, Meenagh G, Ciapetti A, et al. Inter-observer agreement of standard joint counts in early rheumatoid arthritis: A comparison with grey scale ultrasonography — a preliminary study. *Rheumatology* 2008;47:54-8.
3. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. *Arthritis Rheum* 2008;58:2958-67.
4. Scirè CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: Power Doppler signal predicts short-term relapse. *Rheumatology* 2009;48:1092-7.
5. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. *Arthritis Rheum* 2009;60:1915-22.
6. Hau M, Schultz H, Tony HP, Keberle M, Jahns R, Haerten R, et al. Evaluation of pannus and vascularization of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high-resolution ultrasound (multidimensional linear array). *Arthritis Rheum* 1999;42:2303-8.
7. Kane D, Balint PV, Sturrock RD. Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. *J Rheumatol* 2003;30:966-71.
8. Karim Z, Wakefield RJ, Quinn M, Conaghan PG, Brown A, Veale DJ, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: A comparison with arthroscopy and clinical examination. *Arthritis Rheum* 2004;50:387-94.
9. Szkudlarek M, Narvestad E, Klarlund M, Court-Payen M, Thomsen HS, Østergaard M. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis comparison with magnetic resonance imaging, conventional radiography and clinical examination. *Arthritis Rheum* 2004;50:2103-12.
10. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of inflammatory activity in rheumatoid arthritis: A comparative study of clinical evaluation with gray-scale and power Doppler ultra-sonography. *Ann Rheum Dis* 2005;64:375-81.
11. Brown AK. Using ultrasonography to facilitate best practice in diagnosis and management of RA. *Nat Rev Rheumatol* 2009; 5:698-706.
12. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Østergaard M. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. *Arthritis Rheum* 2003;48:955-62.
13. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. *Arthritis Rheum* 2004;50:1107-16.
14. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D'Agostino MA, Backhaus M, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: A comparative study between clinical examination and ultrasound. *Ann Rheum Dis* 2012 Jun 7. [E-pub ahead of print]
15. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis Rheum* 2006;54:47-53.
16. Hau M, Kneitz C, Tony HP, Keberle M, Jahns R, Jenett M. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). *Ann Rheum Dis* 2002;61:55-8.
17. Ribbens C, André B, Marcelis S, Kaye O, Mathy L, Bonnet V, et al. Rheumatoid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: Pilot study. *Radiology* 2003;229:562-9.
18. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. *Ann Rheum Dis* 2006;65:1433-7.
19. Fiocco U, Ferro F, Vezzù M, Cozzi L, Checchetto C, Sfriso P, et al. Rheumatoid and psoriatic knee synovitis: Clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. *Ann Rheum Dis* 2005;64:899-905.
20. Iagnocco A, Filippucci E, Perella C, Ceccarelli F, Cassarà E, Alessandri C, et al. Clinical and ultrasonographic monitoring of response to adalimumab treatment in rheumatoid arthritis. *J Rheumatol* 2008;35:35-40.
21. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al; OMERACT 7 Special Interest Group. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. *J Rheumatol* 2005;32:2485-7.
22. Wakefield RJ, D'Agostino MA, Iagnocco A, Filippucci E, Backhaus M, Scheel AK, et al. The OMERACT Ultrasound Group: Status of current activities and research directions. *J Rheumatol*

- 2007;34:848-51.
23. Schmidt WA, Schmidt H, Schicke B, Gromnica-Ihle E. Standard reference values for musculoskeletal ultrasonography. *Ann Rheum Dis* 2004;63:988-94.
 24. Naredo E, Gamero F, Bonilla G, Uson J, Carmona L, Laffon A. Ultrasonography assessment of inflammatory activity in rheumatoid arthritis: Comparison of extended versus reduced joint evaluation. *Clin Exp Rheumatol* 2005;23:881-7.
 25. Naredo E, Rodríguez M, Campos C, Rodríguez-Heredia JM, Medina JA, Giner E, et al; Ultrasound Group of The Spanish Society of Rheumatology. Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. *Arthritis Rheum* 2008;59:515-22.
 26. Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: A pilot project. *Arthritis Rheum* 2009;61:1194-201.
 27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
 28. Jousse-Joulin S, d'Agostino MA, Marhadour T, Albert JD, Bentin J, Chary Valckenaere I, et al. Reproducibility of joint swelling assessment by sonography in patients with long-lasting rheumatoid arthritis (SEA-Repro study part II). *J Rheumatol* 2010;37:938-45.
 29. Marhadour T, Jousse-Joulin S, Chalès G, Grange L, Hacquard C, Loeuille D, et al. Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). *J Rheumatol* 2010;37:932-7.
 30. Bruyn GA, Pineda C, Hernandez-Diaz C, Ventura-Rios L, Moya C, Garrido J, et al. Validity of ultrasonography and measures of adult shoulder function and reliability of ultrasonography in detecting shoulder synovitis in patients with rheumatoid arthritis using magnetic resonance imaging as a gold standard. *Arthritis Care Res* 2010;62:1079-86. Erratum in: *Arthritis Care Res* 2010;62:1514.
 31. Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA, et al. Summary findings of a systematic review of the ultrasound assessment of synovitis. *J Rheumatol* 2007;34:839-47.
 32. Luukkainen RK, Saltyshev M, Koski JM, Huhtala HS. Relationship between clinically detected joint swelling and effusion diagnosed by ultrasonography in metatarsophalangeal and talocrural joints in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2003;21:632-4.
 33. Luukkainen R, Sanila MT, Luukkainen P. Poor relationship between joint swelling detected on physical examination and effusion diagnosed by ultrasonography in glenohumeral joints in patients with rheumatoid arthritis. *Clin Rheumatol* 2007;26:865-7.
 34. Luukkainen R, Sanila MT, Saltyshev M, Huhtala H, Koski JM. Relationship between clinically detected joint swelling and effusion diagnosed by ultrasonography in elbow joints in patients with rheumatoid arthritis. *Clin Rheumatol* 2005;24:228-31.
 35. Dougados M, Jousse-Joulin S, Mistretta F, d'Agostino MA, Backhaus M, Bentin J, and al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: Results from a prospective multicentre study of rheumatoid arthritis. *Ann Rheum Dis* 2010;69:828-33.
 36. Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography scores: All different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. *Arthritis Res Ther* 2011;13:R78.
 37. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, and al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: Evidence from an imaging study may explain structural progression. *Arthritis Rheum* 2006; 54:3761-73.
 38. Mandl P, Naredo E, Wakefield RJ, Conaghan PG, D'Agostino MA; OMERACT Ultrasound Task Force. A systematic literature review analysis of ultrasound joint count and scoring systems to assess synovitis in rheumatoid arthritis according to the OMERACT filter. *J Rheumatol* 2011;38:2055-62.
 39. Backhaus M, Burmester GR, Sandrock D, Loreck D, Hess D, Scholz A, et al. Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. *Ann Rheum Dis* 2002;61:895-904.
 40. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, Ostergaard M. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: A comparison with dynamic magnetic resonance imaging. *Arthritis Rheum* 2001;44:2018-23.
 41. Lindegaard H, Vallø J, Hørslev-Petersen K, Junker P, Østergaard M. Low field dedicated magnetic resonance imaging in untreated rheumatoid arthritis of recent onset. *Ann Rheum Dis* 2001; 60:770-6.
 42. Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S, et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. *Arthritis Rheum* 2012;64:67-76.